PharVision Advisers’s Kirby Corp KEX Stock Holding History

PharVision Advisers’s Portfolio KEX Stock Details KEX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,270	Closed	-$360K	–	389
2025 Q4	$360K	Buy	+3,270	New	+$332K	0.18%	167
2025 Q1	–	Sell	-2,423	Closed	-$256K	–	401
2024 Q4	$256K	Buy	+2,423	New	+$292K	0.22%	212

Other funds holding KEX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Luther King Capital Management (LKCM) Fort Worth, Texas $23.1B AUM 21.31% 1-Year Est. Return

PharVision Advisers's KEX Position: Q1 2026 in Review

PharVision Advisers sold out of Kirby Corp (KEX) in Q1 2026, closing a stake of 3,270 shares — an estimated $360K sold.

PharVision Advisers first reported a position in KEX in Q4 2024 and held it in 2 quarters. The position peaked at $360K in Q4 2025. 432 funds tracked by Wall St. Rank hold KEX as of Q1 2026.

PharVision Advisers reported no remaining Kirby Corp position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 3,270 Kirby Corp shares in Q1 2026, an estimated $360K.
PharVision Advisers first reported a position in Kirby Corp in Q4 2024 and held it in 2 quarters.
PharVision Advisers's Kirby Corp position peaked at $360K in Q4 2025.
432 funds tracked by Wall St. Rank held Kirby Corp as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.